<?xml version='1.0' encoding='utf-8'?>
<document id="30556034"><sentence text="Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation."><entity charOffset="0-10" id="DDI-PubMed.30556034.s1.e0" text="Sofosbuvir" /><entity charOffset="12-23" id="DDI-PubMed.30556034.s1.e1" text="Velpatasvir" /><entity charOffset="29-41" id="DDI-PubMed.30556034.s1.e2" text="Voxilaprevir" /><pair ddi="false" e1="DDI-PubMed.30556034.s1.e0" e2="DDI-PubMed.30556034.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30556034.s1.e0" e2="DDI-PubMed.30556034.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30556034.s1.e0" e2="DDI-PubMed.30556034.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30556034.s1.e1" e2="DDI-PubMed.30556034.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30556034.s1.e1" e2="DDI-PubMed.30556034.s1.e2" /></sentence><sentence text="There are limited data on direct-acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation" /><sentence text=" Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs"><entity charOffset="1-11" id="DDI-PubMed.30556034.s3.e0" text="Sofosbuvir" /><entity charOffset="12-23" id="DDI-PubMed.30556034.s3.e1" text="velpatasvir" /><entity charOffset="24-36" id="DDI-PubMed.30556034.s3.e2" text="voxilaprevir" /><pair ddi="false" e1="DDI-PubMed.30556034.s3.e0" e2="DDI-PubMed.30556034.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30556034.s3.e0" e2="DDI-PubMed.30556034.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30556034.s3.e0" e2="DDI-PubMed.30556034.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30556034.s3.e1" e2="DDI-PubMed.30556034.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30556034.s3.e1" e2="DDI-PubMed.30556034.s3.e2" /></sentence><sentence text=" We report the first published experience using SOF/VEL/VOX after liver transplantation for a DAA-experienced patient with severe hepatitis due to early recurrent GT3 HCV" /><sentence text=" The patient was treated with SOF/VEL/VOX that was extended to a total duration of 16 weeks and was intensified with ribavirin (RBV) starting at week 8 due to persistent viremia during treatment"><entity charOffset="117-126" id="DDI-PubMed.30556034.s5.e0" text="ribavirin" /><entity charOffset="128-131" id="DDI-PubMed.30556034.s5.e1" text="RBV" /><pair ddi="false" e1="DDI-PubMed.30556034.s5.e0" e2="DDI-PubMed.30556034.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30556034.s5.e0" e2="DDI-PubMed.30556034.s5.e1" /></sentence><sentence text=" Sustained virologic response at 12 weeks (SVR12) after treatment completion was achieved" /><sentence text=" SOF/VEL/VOX was well tolerated, and immediate drug-drug interaction (DDI) with tacrolimus (TAC) was not evident"><entity charOffset="80-90" id="DDI-PubMed.30556034.s7.e0" text="tacrolimus" /><entity charOffset="92-95" id="DDI-PubMed.30556034.s7.e1" text="TAC" /><pair ddi="false" e1="DDI-PubMed.30556034.s7.e0" e2="DDI-PubMed.30556034.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30556034.s7.e0" e2="DDI-PubMed.30556034.s7.e1" /></sentence><sentence text=" Due to improvement in liver metabolic function with increasing TAC clearance, TAC dose adjustment was required throughout the treatment course"><entity charOffset="64-66" id="DDI-PubMed.30556034.s8.e0" text="TAC" /><entity charOffset="79-81" id="DDI-PubMed.30556034.s8.e1" text="TAC" /><pair ddi="false" e1="DDI-PubMed.30556034.s8.e0" e2="DDI-PubMed.30556034.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30556034.s8.e0" e2="DDI-PubMed.30556034.s8.e1" /></sentence><sentence text=" Conclusion: SOF/VEL/VOX can be considered for treatment of recurrent HCV after transplantation" /><sentence text=" Further study is needed to establish safety and efficacy and define treatment duration in difficult-to-treat populations" /><sentence text="" /></document>